User profiles for "author:Fabiana Rollini"
Fabiana RolliniPost Doctoral Research Associate, University of Florida, Jacksonville Verified email at jax.ufl.edu Cited by 4031 |
International Expert Consensus on Switching Platelet P2Y12 Receptor–Inhibiting Therapies
Dual antiplatelet therapy with aspirin and a P2Y12 inhibitor is the treatment of choice for the
prevention of atherothrombotic events in patients with acute coronary syndromes and for …
prevention of atherothrombotic events in patients with acute coronary syndromes and for …
Guided versus standard antiplatelet therapy in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis
Background Whether guided selection of antiplatelet therapy in patients undergoing
percutaneous coronary intervention (PCI) is effective in improving outcomes compared with …
percutaneous coronary intervention (PCI) is effective in improving outcomes compared with …
Aspirin-free strategies in cardiovascular disease and cardioembolic stroke prevention
D Capodanno, R Mehran, M Valgimigli… - Nature Reviews …, 2018 - nature.com
In patients with manifestations of cardiovascular disease, acetylsalicylic acid (popularly
known as aspirin) has been the mainstay of treatment for decades owing to its capacity to …
known as aspirin) has been the mainstay of treatment for decades owing to its capacity to …
Comparative effects of guided vs. potent P2Y12 inhibitor therapy in acute coronary syndrome: a network meta-analysis of 61 898 patients from 15 randomized trials
Aims Guidelines recommend the use of potent P2Y12 inhibitors over clopidogrel for the
reduction of ischaemic events in patients with acute coronary syndrome (ACS). However …
reduction of ischaemic events in patients with acute coronary syndrome (ACS). However …
Impaired Responsiveness to the Platelet P2Y12 Receptor Antagonist Clopidogrel in Patients With Type 2 Diabetes and Coronary Artery Disease
DJ Angiolillo, JA Jakubowski, JL Ferreiro… - Journal of the American …, 2014 - jacc.org
Background: Several studies have shown that patients with diabetes mellitus (DM) exhibit an
impaired response to clopidogrel. This may contribute to their increased risk of recurrent …
impaired response to clopidogrel. This may contribute to their increased risk of recurrent …
Switching P2Y12-receptor inhibitors in patients with coronary artery disease
Dual antiplatelet therapy—the combination of aspirin and a P2Y 12-receptor inhibitor—is the
cornerstone of treatment of patients with acute coronary syndromes (ACS) and of those …
cornerstone of treatment of patients with acute coronary syndromes (ACS) and of those …
Defining strategies of modulation of antiplatelet therapy in patients with coronary artery disease: a consensus document from the academic research consortium
D Capodanno, R Mehran, MW Krucoff, U Baber… - Circulation, 2023 - Am Heart Assoc
Antiplatelet therapy is the mainstay of pharmacologic treatment to prevent thrombotic or
ischemic events in patients with coronary artery disease treated with percutaneous coronary …
ischemic events in patients with coronary artery disease treated with percutaneous coronary …
Platelet inhibition with ticagrelor 60 mg versus 90 mg twice daily in the PEGASUS-TIMI 54 trial
Abstract Background: The PEGASUS-TIMI 54 (Prevention of Cardiovascular Events in
Patients with Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of …
Patients with Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of …
Safety and efficacy of different prophylactic anticoagulation dosing regimens in critically and non-critically ill patients with COVID-19: a systematic review and meta …
L Ortega-Paz, M Galli, D Capodanno… - European Heart …, 2022 - academic.oup.com
Background The clinical impact of different prophylactic anticoagulation regimens among
hospitalized patients with coronavirus disease 2019 (COVID-19) remains unclear. We …
hospitalized patients with coronavirus disease 2019 (COVID-19) remains unclear. We …
Platelet inhibition with cangrelor and crushed ticagrelor in patients with ST-segment–elevation myocardial infarction undergoing primary percutaneous coronary …
Background: The platelet inhibitory effects induced by oral P2Y12 receptor antagonists are
delayed in patients with ST-segment–elevation myocardial infarction undergoing primary …
delayed in patients with ST-segment–elevation myocardial infarction undergoing primary …